

CONFORM Pivotal Trial

eCRF Completion Guidelines

Contents

Contents.....	1
1 General Instructions.....	3
1.1 Database Access and Security	3
1.2 Forgotten Password.....	4
1.3 System Timeout.....	4
2 Adding and Viewing Subjects.....	5
2.1 Add Subject.....	5
2.2 Randomization.....	5
2.3 Subject Record Grid.....	6
2.4 Visit Window List.....	7
3 Individual CRF Instructions.....	8
3.1 Screening and Randomization	8
3.1.1 Informed Consent	8
3.1.2 Medical History	8
3.1.3 Vital Signs	10
3.1.4 Inclusion/Exclusion Criteria.....	10
3.1.5 Echocardiogram/CT.....	10
3.1.6 Patient Population.....	11
3.2 Index Procedure and Pre-Discharge	11
3.2.1 LAA Measurements	11
3.2.2 CLAAS Implant/Control Implant.....	12
3.2.3 Pre-Discharge	12
3.3 Adverse Events	12
3.3.1 Inactivating Adverse Event Forms.....	13
3.4 Unscheduled Visit.....	14
3.5 Reconsent.....	14
3.6 Study Exit.....	15
3.6.1 Screen Failure.....	15
3.6.2 Withdrawn	16
3.6.3 Subject Death.....	17
4 Data Management	18

CONFORM Pivotal Trial

eCRF Completion Guidelines

4.1	Data Queries	18
4.2	Mandatory Fields and Edit Checks	19
4.3	Changing Previously Entered Data	19
4.4	Unknown Date Entry	20
4.5	Inactivating Log Lines	20
5	Imaging Uploads	21
6	Conclusion	22
7	Contact Information	23
8	Revision History	23

CONFORM Pivotal Trial

eCRF Completion Guidelines

1 General Instructions

Note: These instructions are specific to the database as applies to patients consented under Protocol Revision K. If you need instructions for patients consented under an earlier Protocol Revision, please ask your site manager for the eCRF Completion Guidelines Version 1.0.

1.1 Database Access and Security

Rave Database Link:

<https://login.imedidata.com/login>

Existing users: You will receive an email from Medidata, informing you of access to the study. Depending on the user's role for the study, additional eLearning may be required prior to gaining access to the study EDC. Pending eLearning will be displayed on the home screen and can be accessed via the "View courses" link.

You must complete required courses.

You cannot access 55 of your assigned studies until you successfully complete the required eLearning courses.

[View courses](#) 

New users:

Request access through your assigned Conformal Site Manager, who will work with you to ensure appropriate training and documentation is in place prior to providing access.

A User Authorization Form will then be sent to you for signature via DocuSign. Once the form is completed and processed by the study team, an email invitation is sent to the end user for account activation. Required training (eLearning) videos in Medidata must be completed to gain access to the study database. The eLearning trainings can be accessed via the "View courses" link in the message displayed on the homepage.

You must complete required courses.

You cannot access 55 of your assigned studies until you successfully complete the required eLearning courses.


[View courses](#) 

Upon logging into Medidata Rave, the study can be accessed via "Studies" then "All studies."

CONFORM Pivotal Trial

eCRF Completion Guidelines


 Clients ▾ Study groups ▾ Studies ▲ Sites ▾



Once accessed, the study will then appear in your Recent Activity menu on the homepage and can also be accessed via “All studies” in that menu.

1.2 Forgotten Password

Welcome, please sign in



1. Open [iMedidata](#)
2. Click the link “I forgot my username or password”
3. Enter your email address and click “send”
4. In a few minutes, **check your email inbox** for an email invite to iMedidata
 - **IMPORTANT: The reset link in this email will only be valid for 4 hours. After 4 hours the link will expire and you will need to repeat the process.**
5. Open the email and click on “reset password”
6. Answer your security question (ie: your birthday date) and click “reset”
7. Type in your new password and confirm.
8. Login to [iMedidata](#) with your username and new password

<https://login.imedidata.com/login>

1.3 System Timeout

The system will time out after 15 minutes of inactivity. Make sure to save your data often.

If data is not saved and the system times out, the data will need to be re-entered. Click the  button at the bottom of the form.


CONFORM Pivotal Trial

eCRF Completion Guidelines


2 Adding and Viewing Subjects

2.1 Add Subject

To add a subject, click the + Add Subject  icon in the upper right corner of the screen, which will take you to the New Subject record.



Check the box next to “Check to create subject.” The subject is added into the system when the record is saved.



The screenshot shows the 'New Subject' form. At the top, there are two tabs: 'New Subject' and 'Subject'. Below the tabs is a checkbox labeled 'Check to create subject' which is checked. A red arrow points to this checkbox. Below the checkbox are several input fields: 'Site Number (auto-populated)', 'Subject Number (auto-populated)', and 'Subject ID (auto-populated)'. At the bottom of the form, there is a link for 'eCRF Completion Guidelines' and two buttons: 'Save' (highlighted with a red box) and 'Cancel'.

After the subject has been added, the subject will be enrolled in one of the following two categories:

ROLL-IN: Up to 3 subjects per site may be implanted with the CLAAS device as part of the roll-in phase of the trial. Sites that implanted 3 subjects with the Initial CLAAS system will be permitted to implant one additional roll-in subject with the Next Generation CLAAS System.

RANDOMIZED: When the subject has met all inclusion criteria and no exclusion criteria (including echocardiographic exclusion criteria), the subject will be randomized to either the CLAAS or Control device.

The category will be entered on the Informed Consent form (see [3.1.1 Informed Consent](#)).

It is important to only add a subject in EDC after the subject has signed the informed consent form, as this action cannot be undone. If a new subject is entered into the database in error, contact your Site Manager immediately.

2.2 Randomization


When the subject has met all inclusion criteria and no exclusion criteria (including echocardiographic exclusion criteria), the subject will be randomized to either the CLAAS or Control device.

The LAA occlusion procedure shall take place no later than 14 days from the date of randomization.

Please ensure that more than one Study Personnel listed on your DOA has the ability to randomize subjects within the iMedidata system.

CONFORM Pivotal Trial

eCRF Completion Guidelines



21901-017 Randomization

Randomization

Requires Verification Requires Signature

Check here to randomize subject Verify

CAUTION: Saving this form will result in randomization for this subject.


Please confirm that this is the intended action and all inclusion/exclusion criteria have been met/not met including echo eligibility criteria.

A Protocol Deviation is required if:

- Randomization occurs **greater than 90 days** from Original Informed Consent.
- Implant Procedure date is **greater than 14 days** from Randomization date.

2.3 Subject Record Grid

Subject case report forms can be accessed one of two ways – either from the folders on the far-left side of the screen as indicated by the left arrow or from the subject grid as indicated by the middle arrow.



medidata

conformalmedical 21-101 EDC User Acceptance Testing 21901 - Conformal Test... 21901-051 Help EDC - CRC Paula Hicks

21901-051

Subject Status: Screening

eCRF Completion Guidelines

Screening

Study Completion / Early Termination

Concomitant Medication/ Therapy

Protocol Deviations

Imaging Summary Data

Action View Subject Reports

Primary Form Select Event... Add Event

	Subject	Screening	Study Completion / Early Termination	Concomitant Medication/ Therapy	Protocol Deviations	Imaging Summary Data
Subject						
Informed Consent		O				
Demographics		O				
Medical History		O				
Vital Signs		O				

Note: Subject specific reports are also available for use and can be accessed using the link as indicated by the right arrow.

To return to the subject grid while in an individual case report form, click on the **Subject Record ID** link as indicated below, and it will return you to the subject grid. The image below is on the Informed Consent form.

CONFORM Pivotal Trial

eCRF Completion Guidelines

21901-001 Screening

Informed Consent

Requires Signature

Subject to be enrolled as **Roll-In**

Did patient sign consent? **Yes**

2.4 Visit Window List

Once the date of procedure has been entered into the Procedure form, the Visit Window list will populate within the Visit Window folder on the left side of the screen. The earliest date and latest date for each study visit are listed on this form, calculated by the system using the protocol-specified visit windows.

21901-302

Patient Status Randomized

Date of Procedure 18 DEC 2024

eCRF Completion Guidelines

18 Dec 2029 (projected)

Device Deficiency 18 Dec 2029 (projected)

Concomitant Medication/Therapy 18 Dec 2029 (projected)

Protocol Deviations 18 Dec 2029 (projected)

Imaging Summary Data

Image/Document Submission Details

Workflow Summary

Visit Window (1)

Visit Window

21901-302 Visit Window (1)

Visit Window

Please note this page is intended to be informative only. Please consult your Site Manager if you have questions about the subject's follow-up visit schedule.

Date of Procedure (Day 0)	18 DEC 2024	<input type="radio"/> Verify
Day 7 Visit		
Earliest Date	25 DEC 2024	<input type="radio"/> Verify
Latest Date	27 DEC 2024	<input type="radio"/> Verify
Day 45 Visit		
Earliest Date	25 JAN 2025	<input type="radio"/> Verify
Latest Date	08 FEB 2025	<input type="radio"/> Verify

CONFORM Pivotal Trial

eCRF Completion Guidelines

3 Individual CRF Instructions

3.1 Screening and Randomization

3.1.1 Informed Consent

Please confirm the subject you are randomizing is in the roll-in or randomized category. If subject Randomization occurs **greater than 90 days** from the date of informed consent, a PD must be entered.

ICF Version (xx.xx): Enter the Version of the ICF as recognized by the site and will be recognized for monitoring purposes. Even though the format is listed as (xx.xx), both text and number values can be entered. It is suggested that date of ICF IRB approval be entered here, e.g., 18NOV2024.

If a subject was screen failed previously and is being reconsidered for the study, please enter information regarding prior subject ID on this page.

Protocol Revision Activated to:	J ▼
ICF Version (xx.xx)	18NOV2024
Was this subject screened previously?	<input checked="" type="radio"/> Yes <input type="radio"/> No
Previous Subject ID (xxxxxxx)	21901-58

3.1.2 Medical History

Medical history may be completed up to 30 days prior to consent as part of site standard of care. If it is completed greater than 30 days prior to the date of informed consent, a protocol deviation must be entered.

Medical history must be completed prior to index procedure for roll-in subjects and prior to randomization for randomized subjects.

Auto queries will populate for "Yes" responses as related to Inclusion/Exclusion Criteria (e.g., History of CVA, History of Intracardiac Thrombus, etc.).

CONFORM Pivotal Trial

eCRF Completion Guidelines

History of intracardiac mass, thrombus or vegetation? Yes No Unknown

Data Entry Error

Please confirm patient does not meet echo exclusion criteria of intracardiac thrombus or dense spontaneous echo contrast consistent with thrombus, as visualized by TEE PRIOR to implant.

Rationale for seeking a non-pharmacologic alternative to OAC (Check all that apply)

The screenshot shows the 'Medical History' section of the eCRF. A sidebar on the left lists various data points like 'Screening', 'Informed Consent', 'Demographics', 'Medical History', 'Vital Signs', etc. The main content area is titled 'Medical History' and includes a date field for 'Date Medical History Performed'. Below this is a section titled 'Rationale for seeking a non-pharmacologic alternative to OAC (Check all that apply)'. This section contains a list of reasons with checkboxes: 'Drug regimen not compatible with OAC', 'Non-compliance to medication or monitoring schedule', 'History of bleeding or high bleeding risk', 'Renal failure', 'High Fall Risk', and 'Other'. A red box highlights the checkboxes for the first five items.

To meet study inclusion, at least one of the boxes must be checked or “other” should be selected with information entered (i.e., occupational hazard risks, financial issues, etc.).

Every effort should be made to collect definitive yes/no responses from the Subject Medical Record. Your response may prompt queries to assess if any inclusion/exclusion criteria has not/has been met in relation to your response.

History of procedure to convert atrial fibrillation or atrial flutter? If both ablation and cardioversion have been performed for the subject, choose the procedure performed closest to screening data collection.

History of procedure to convert atrial fibrillation or atrial flutter?

Yes

No

Unknown

Prior cerebral vascular accident?

- If subject had a spontaneous brain hemorrhage, please only select “Yes”
- If subject had a brain hemorrhage as a result of a fall or trauma, please select “No” (if no other stroke) and response “Yes” to **Prior traumatic intracranial hemorrhage?**

CONFORM Pivotal Trial

eCRF Completion Guidelines

Prior cerebral vascular accident? Yes
 No
 Unknown

Prior traumatic intracranial hemorrhage? Yes
 No
 Unknown

Protocol Deviations are required to be reported for the following:

- Physical Exam and NYHA **greater than 30 days** prior to informed consent
- Lab collection at screening **greater than 60 days** prior to informed consent

3.1.3 Vital Signs

Vital signs are required to be collected and entered in EDC for Screening. Vital signs are not required at any other study visit and do not need to be entered into EDC for other visits.

Screening vital signs may be collected per site standard of care up to 60 days prior to informed consent.

3.1.4 Inclusion/Exclusion Criteria

All patients must have CT or TEE Imaging prior to randomization. Conformal can support same day randomization (using the Procedural TEE) only if you have 3+ cases on any given day.

If “Have all the inclusion criteria and none of the exclusion criteria, as specified by the protocol, been met for this subject?” is answered “No,” each individual Inclusion/Exclusion criteria will become visible.

For Screen Failed subjects, “N/A – Not assessed” may be selected for any criteria not assessed prior to the subject screen failure.

3.1.5 Echocardiogram/CT

Screening imaging (TEE or CT) must be performed prior to randomization. If more than one Imaging was performed, select “Save and Add Another Line” to create a new Echocardiogram/CT Form within the EDC.



All Imaging Log Lines can be visualized by selecting “Echocardiogram/CT”. Please upload all images into the Imaging Module.

CONFORM Pivotal Trial

eCRF Completion Guidelines

	Was echocardiogram/CT completed? <i>If no, complete a protocol deviation.</i>	Why is unscheduled imaging being performed?	Other, specify:
1	Yes		
2	Yes		
3			

A protocol deviation is required for screening imaging performed **greater than 6 months** prior to informed consent.

3.1.6 Patient Population

The responses to the questions in the *Patient Population* Form trigger what forms will become available for this subject's completion in EDC. Please hover over the question mark for guidance on the subject's required follow-up visits and patient exit classification.

Did patient meet eligibility criteria before the Procedure Day? **Yes**

The responses to these questions trigger what forms will become available for this subject's completion in

If the subject did not meet eligibility criteria before the Procedure Day, the subject should be exited as a "Screen Failure – Subject did not meet I/E criteria prior to index procedure." Please complete the study exit form accordingly.

before the Procedure Day?

Verify

3.2 Index Procedure and Pre-Discharge

3.2.1 LAA Measurements

The *LAA Measurements* form is located in the Index Procedure folder. If the subject was implanted with the control device, LAA measurements should be collected per the control device's IFU. Only the **LAA Ostium Diameter** and **LAA Maximum length** are required for a control device. A Protocol deviation is *not* required if the LAA Perpendicular Depth was not obtained for a control device.

CONFORM Pivotal Trial

eCRF Completion Guidelines

Angle	LAA Ostium Diameter (xx.xx)	LAA Perpendicular Depth (xx.xx)	LAA Maximum Length (xx.xx)
0 degrees	mm	mm	mm
45 degrees	mm	mm	mm
90 degrees	mm	mm	mm
135 degrees	mm	mm	mm

3.2.2 CLAAS Implant/Control Implant

Either the *CLAAS Implant* form or *Control Implant* form will populate in the Index Procedure folder, depending on the device assigned to the subject in EDC. These forms are log line style forms, allowing for more than one device to be entered. All devices that are used or opened for this subject should be entered, including any that are opened but not used.

If needed, additional log lines can be added by clicking “Save and Add Another Line.”

21901-303 Index Procedure (Day 0)

Control Implant

Control Implant, Log Lines

Back To Complete View < Previous Line Line 1 of 1 Next Line > Save and Add Another Line

Control Product

- Amulet
- WATCHMAN FLX
- WATCHMAN FLX PRO

3.2.3 Pre-Discharge

On the *Visit Information* form, the duration between the Pre-discharge TTE and the time of access sheath removal will be automatically calculated by EDC using the time of the pre-discharge TTE entered in this form and the time of access sheath removal in the *Procedure* form.


A protocol deviation must be entered if the time between access sheath removal and pre-discharge TTE is **less than four hours**.

3.3 Adverse Events

To enter Adverse Events, select “Adverse Event” in the dropdown on the upper right-hand corner of the EDC page. Click on Add Event. Then, the Adverse Event CRF will populate in the grid.

CONFORM Pivotal Trial

eCRF Completion Guidelines



The adverse events will populate towards the far right of the grid as individual events. They can be accessed by clicking on the radio button associated with the event.

Responses marked “Yes” under “Adverse Events with special interest?” may generate additional forms. For example, if Bleeding Event is marked “Yes,” a Bleeding Event form will populate for completion.

The CONFORM Pivotal Trial does not collect ALL AEs. Site Personnel should refer to the most current version of the CONFORM Pivotal Trial Protocol with attention to Section 12 Safety Reporting: Reportable Events by Investigational Sites and Safety Event Definitions.

AE entry into the Database is considered the Date Sponsor Notified of AE. If RC does not have access to the database or is not yet sure if a discovered/reported event meets protocol specified reporting criteria, the RC should notify their Site Manager via email or phone call and file a printed copy of this notification in the Subject Binder. Alternatively, the site may notify the Sponsor via email at:

Safety@conformalmedical.com

Event Reporting emails should include the following: Subject ID, date of awareness, start date, and suspected AE Term.

3.3.1 Inactivating Adverse Event Forms

If an AE has been entered in error, has been reviewed to be not reportable per protocol, or can be combined with another AE, it may be necessary to inactivate the AE Form. AE form inactivation requests will be documented via query, which will be added by the Site Manager, Safety or Clinical Data Manager to confirm the site agrees with the inactivation. The Research Coordinator (RC) should respond to the query with clear confirmation that the form is to be inactivated.

Status of Adverse Event	New adverse event	<input type="radio"/> Verify
Adverse Event Term	TEST	<input type="radio"/> Verify
<p> This AE does not meet event reporting criteria. Should this event be inactivated? Please confirm. </p> <p> Yes, please inactivate</p> <p><input type="button" value="Re-Query"/> <input type="button" value="Close"/></p>		

CONFORM Pivotal Trial

eCRF Completion Guidelines

If the **site** identifies an AE form that needs to be inactivated, an email should be sent to the site CRA confirming the following information:

Subject Line of email: CONFORM [Site #] AE Inactivation Request

Body of email:

Please inactivate the following Adverse Event(s) from the EDC:

Subject #:

AE # / AE Term


Reason for inactivation (e.g., duplicate of AE X, does not meet reporting requirements per protocol)

Once the email is received, the CRA will open a query to the DM (so no response is required from the site) confirming the form is to be inactivated.

Please contact your assigned Site Manager if you have any questions regarding AE data entry.

3.4 Unscheduled Visit

To enter an unscheduled visit, select “Unscheduled Visit” in the dropdown on the upper right-hand corner of the EDC page. Click on Add Event. The Unscheduled Visit CRF will populate in the grid. For example, per protocol, subjects with a suspected stroke shall be documented as an Unscheduled Visit in the Electronic Database System.



3.5 Reconsent

To enter a reconsent, select “Reconsent” in the dropdown on the upper right-hand corner of the EDC page. Click on Add Event. The Reconsent CRF will populate in the grid.

CONFORM Pivotal Trial

eCRF Completion Guidelines

The screenshot shows the 'Actions' section of the eCRF. On the right, there is a link for 'View Patient Reports'. Below this, the 'Primary Form' dropdown menu is open, showing a search bar 'Select Event...' and an 'Add Event' button. The dropdown list contains four items: 'Adverse Event', 'Reconsent' (which is highlighted in blue), and 'Unscheduled Visit'.

3.6 Study Exit

The CONFORM Pivotal Trial has provided a Study Exit Flowchart in MOP-13. Refer to this Flowchart in determining Study Exit timepoints for your subject. Note that responses entered on the [Patient Population](#) form directly impact the Study Exit form.

The following four categories of Subject Classification will be tracked as documented in EDC on the Study Exit Form.

- **Screen Failure**
- **Withdrawn**
- **Subject Death**
- **Completed Study**

3.6.1 Screen Failure

The following three categories of Screen Failure will be tracked on the Study Exit form. Specific reasons for the screen failure must also be documented.

1. Subject did not meet I/E criteria prior to index procedure (Note: if subject was randomized, please do not select this box)
2. Subject did not meet I/E criteria after the Index Procedure TEE was performed and prior to the Access Sheath crossing the body
3. Other Inclusion/Exclusion / Screening Assessment criteria (Note: This should only be chosen if a patient was randomized, but never had the Procedural TEE, and did not meet I/E criteria).

CONFORM Pivotal Trial

eCRF Completion Guidelines

Subject Classification	<input checked="" type="radio"/> Screen Failure <input type="radio"/> Withdrawn <input type="radio"/> Subject Death <input type="radio"/> Completed Study - Subject implanted and completed 5-year follow-up
If subject was a screen Failure, specify reason	<input type="radio"/> Subject did not meet I/E criteria prior to index procedure (Note: If subject was randomized, please do not select this box) ← <input type="radio"/> Subject did not meet I/E criteria after the Index Procedure TEE was performed and prior to the Access Sheath crossed the body <input type="radio"/> Other Inclusion / Exclusion / Screening Assessment criteria
Please briefly describe why the subject exited	<div style="border: 1px solid #ccc; height: 50px; width: 100%;"></div> <p>0 / 200</p>

In Brief Description: enter which I/E criteria has not been met.

For Screen Failures after Procedure TEE performed but prior to Access Sheath (2): it would be expected that the subject has met an Echo Exclusion Criteria, in the Randomization Folder Echocardiographic Exclusion Criteria eCRF: ***Did the subject meet any echo exclusion Criteria per the procedural TEE?*** would be expected to be “Yes.”

Echocardiographic Exclusion Criteria

Requires Verification

Did the patient meet any echo exclusion criteria per the procedural TEE? Yes

Verify

3.6.2 Withdrawn

If a subject has been randomized and Study Exit is not related to Death or Completed Study, *Withdrawn* should be selected for data entry.

At any time point of the study, whether a subject has been randomized or not, if a subject decides to withdraw consent or the Investigator decides to withdraw the subject, *Withdrawn* should also be selected for data entry.

CONFORM Pivotal Trial

eCRF Completion Guidelines

21901-302 Study Completion / Early Termination

Study Exit

Date of Study Exit  Data is required. Please complete.

Subject Classification

- Screen Failure
- Withdrawn
- Subject Death
- Completed Study - Subject implanted and completed 5-year follow-up

If Subject was withdrawn, specify reason

Please briefly describe why the subject exited

...
No Implant (Subject did not receive an implant at the index procedure)
Subject withdrew consent
Subject lost to follow-up
Investigator decision to withdraw subject
Site terminated by Sponsor
Sponsor terminated the study
Subject withdrew due to COVID-19 diagnosis
Subject withdrew due to COVID-19 safety concerns
Other

Move to next task

[View PDF](#) 184 (Clinical Research Coordinator) Rave EDC 2024.2.0 Copyright © 1999-2024 Medidata S

If a randomized subject meets all I/E Criteria at Screening and at Procedure TEE, but does not receive an implant, enter the subject classification as *Withdrawn* and the reason as *No Implant* (as pictured above).

If subject is **lost to follow-up** (subject is unreachable, missed visit has occurred, and site personnel made all reasonable efforts to locate and communicate with subject per protocol requirements), enter the subject classification as *Withdrawn* and the reason as *Subject Lost to Follow-up*.

3.6.3 Subject Death

If Subject Death is chosen the following query will populate: ***Please complete the Adverse Event and Death Form.*** Ensure only one AE has an outcome of Death.

Date of Study Exit and Date of Death should be the same.

Conform Study Appendix A: Definitions: ***Mortality*** should be referenced for determination of Primary cause of death for data entry. Source documentation should be available to monitoring for determination of Cardiovascular/Non-Cardiovascular death. AE Event Term may be updated per Certificate of Death or Autopsy as assessed. Every effort should be made by site research staff to obtain any source related to subject's death and provided to Safety as required.

CONFORM Pivotal Trial


eCRF Completion Guidelines

4 Data Management


4.1 Data Queries

Queries refer to questions or flags raised by the system or study personnel when inconsistencies, missing information, or potential errors are detected within the clinical trial data entered by sites. Queries can be auto generated or created manually by data managers, the safety team, or CRAs.


To reply to a query, enter a response in the field below the query and click “Reply”. If query resolution requires data to be added/updated, please complete/update the field first as you may find the query closes automatically without requiring a response.



A list of each subject’s queries can be accessed through View Subject Reports on the subject page.



Select the Query Detail - Query Detail Report which shows all the queries for the subject.




CONFORM Pivotal Trial


eCRF Completion Guidelines

4.2 Mandatory Fields and Edit Checks

If a required question is not answered, a query will generate stating “Data is required. Please complete.” The query will automatically close when data is entered.



Depending on the response to each field, additional fields may display as needed. Queries may generate based on the data entered such as values or dates or values out of range. Another query example is below:




Reminder: Update the data in fields as needed prior to responding to queries. Most queries will automatically close once data is entered and saved. If the query remains open once data is entered, respond to the query.

4.3 Changing Previously Entered Data

If data is changed for an existing record, the system will require a reason for change.

When a saved response is changed, a box will display below the field with a reason for change. The default reason is “Data Entry Error.” There are three options to choose from on the dropdown list (see image to the right). Select the response that applies. Do this for each field that is changed. Click SAVE at the bottom of the screen when done to save the changes.



CONFORM Pivotal Trial

eCRF Completion Guidelines

4.4 Unknown Date Entry

Date fields occur throughout the forms in the EDC. Some fields will allow a partial date to be entered (but the year will always be required). Date fields that allow a partial date will display the “unknown” options when you click on the calendar next to the date field:

The screenshot shows a date selection interface. On the left is a calendar for January 2025. The days of the week are labeled S, M, Tu, W, Th, F, S. The dates 1 through 18 are visible. The date 3 is highlighted with a dashed blue border. On the right is an 'Unknown' selection panel. It has the title 'Unknown' and the instruction 'Select all that are unknown (you can select up to 3)'. There are two checkboxes: 'Day' and 'Month', both of which are currently unchecked.

For fields that require a full date where you are unable to determine the day, please record as 01MonYYYY in EDC. If unable to determine day **and** month, please record as 01JanYYYY. Every effort should be made to at least obtain an approximate year. Do not enter “UNK” for unknown fields. If the year definitely cannot be determined, this should be recorded as 1901.

4.5 Inactivating Log Lines

In the event that data has been entered in error (i.e., data entered into the wrong subject, study does not require data, entry error, etc.) sites have the ability to inactivate Con Meds, Imaging, and PDs on their own. Adverse Event inactivation process is detailed in the Adverse Event section of this document.

Reminder: Medication assessment data collection includes the use of antiplatelet, anticoagulation and endocarditis prophylactic antibiotic medication only.

Log lines can be inactivated by the site. Click the gear icon at the end of the log line and select “Inactivate.”

CONFORM Pivotal Trial

eCRF Completion Guidelines

21901-001 Concomitant Medication/ Therapy

Concomitant Medication

Requires Verification

This form should include prescribed antiplatelet, anticoagulant, antibiotic therapies from subject's relevant medical history through study exit.

Concomitant Medication, Log Lines

All Search field value. '0' or '1' for checkbox fields.

Name	Type of Drug	Other, specify:	Dose	
1 APIXABAN	Anticoagulant		50	mg [Inactivate]

1 New row(s) 10 per add max Add 1 Row(s) 14 Column(s)

Save Cancel

Inactivate

A popup will display, select “OK” and the change is complete. It is not necessary to save the form.

Inactivate

Select Reason INACT - Data not required

OK Cancel

5 Imaging Uploads

Imaging is uploaded in a separate app within Medidata. To access the app, click “Medical Imaging Clinical Trials” along the top of the Medidata home page.

Overview Adjudicate **Medical Imaging Clinical Trials** MEDS Reporter Rave EDC

Recent activity

Studies

- CONFORM Pivotal Rave EDC (SIMT)
- CONFORM Pivotal Medical Imaging Clinical Trials

All Studies

CONFORM Pivotal Trial

eCRF Completion Guidelines

Clicking the **conformalmedical** link will take you to the next page shown below. Next, click on “Conformal CONFORM Pivotal.”

Trials

Trial Name	Status	Type	Info
Conformal CONFORM Pivotal	Live	Imaging	

You will be directed to the imaging home page, where you can see all patients who are currently in the trial at your site.

Note: there is a folder in EDC called “Imaging Summary Data.” Information will automatically be pulled from the Medidata imaging app into a form in this folder, called “Image/Document Submission Details.” The information in this form cannot be edited in EDC and must be edited within the separate imaging app.

For detailed instructions on navigating the imaging app and uploading images, see the Imaging Upload section of the Manual of Procedures, section 7.

6 Conclusion

If you need additional support with eCRF Completion Guidelines, or if you encounter issues, please reach out to your assigned Site Manager. Further contact information is available on the next page.

CONFORM Pivotal Trial

eCRF Completion Guidelines

Contact Information	
Organization	Name
	conformalsupport@namsa.com
Conformal Medical, Inc. (Sponsor)	<p>Aly Dechert Manager of Clinical Operations adechert@conformalmedical.com 15 Trafalgar Square, Ste. 101 Nashua, NH 03063</p> <p>Michelle Pappas Associate Director, Clinical Safety mpappas@conformalmedical.com 15 Trafalgar Square, Ste. 101 Nashua, NH 03063</p>

Revision History			
Version	Description	Name	Date
1.0	New Document	Paula Hicks	22JUN2022
2.0	Updated all sections to clarify general guidance and form-specific guidance	Briony Macdonald-McMillan	14JAN2025